Search
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System
LV-SMENP Vaccine
go.drugbank.com/drugs/DB15804ExperimentalLV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which
UCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalCDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Asimadoline
go.drugbank.com/drugs/DB05104InvestigationalAsimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalRegramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.
Sodium copper chlorophyllin
go.drugbank.com/drugs/DB16522InvestigationalSCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718
Products: LEXEE CHLORO-CRYPTO SODIUM COPPER CHLOROPHYLLIN 50MG/5ML LIQUIDQS-21
go.drugbank.com/drugs/DB05400InvestigationalAs a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.
Velafermin
go.drugbank.com/drugs/DB06493InvestigationalVelafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract.
N,N-dimethylarginine
go.drugbank.com/drugs/DB01686ExperimentalIt is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid.